Management ChangeAug 5, 2026, 08:33 AM
Onconetix Subsidiary Appoints Co-Founder Ralph Schiess to Board
AI Summary
Onconetix, Inc. announced that its Swiss subsidiary, Proteomedix AG, has appointed Ralph Schiess, PhD, to its Board of Directors. Dr. Schiess is a co-founder of Proteomedix and co-developer of Proclarix®, Onconetix's prostate cancer diagnostic blood test, bringing extensive scientific and commercial expertise. Additionally, Thomas Meier, PhD, was re-elected as Chairman of the Board for an additional one-year term at the Annual General Meeting.
Key Highlights
- Ralph Schiess, PhD, appointed to Proteomedix AG Board of Directors.
- Dr. Schiess is co-founder of Proteomedix and co-developer of Proclarix®.
- He brings over a decade of academic and diagnostic industry experience.
- Thomas Meier, PhD, re-elected as Chairman of the Board for one year.
- Appointments approved at PMX Annual General Meeting on June 22, 2026.
Price Impact
More from ONCO